NCT07185490View on ClinicalTrials.gov

CT103d for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 15, 2027

Study Completion Date

August 15, 2029

Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)Plasma Cell Leukemia (PCL)
Interventions
BIOLOGICAL

CT103d

CT103d is a personalized, BCMA-targeted, genetically modified autologous T-cell immunotherapy product.

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER